Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-2808 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-2808 | EXPERIMENTAL | Participants will receive mRNA-2808. |
| Name | Type | Description |
|---|---|---|
| mRNA-2808 | DRUG | intravenous |
Key Inclusion Criteria: * RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody. * Measurable disease defined as at least 1 of the following: * Serum M-protein ≥0.5 grams/deciliter * Urine M-protei...
Top 20 of 25 competitors
mRNA-2808 is an investigational therapy being developed for the treatment of relapsed or refractory multiple myeloma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
mRNA-2808 is being developed by Moderna, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol MRNA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
mRNA-2808 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still being studied in clinical trials to assess its safety and effectiveness.
mRNA-2808 is being studied in a Phase 1 clinical trial with the identifier NCT07116616. This trial is recruiting participants with relapsed or refractory multiple myeloma in the United States and aims to enroll approximately 166 participants aged 18 years and older.
Yes, mRNA-2808 is classified as a small molecule therapeutic. It is being investigated for its potential role in treating relapsed or refractory multiple myeloma, a type of blood cancer.